WVE

2.5655.70%
AG

Adrian George Rawcliffe

Independent Director

Mr. Adrian George Rawcliffe, also known as Ad, serves as Director at Prologue Medicines, Inc. since October 2026. He had been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019 until November 14, 2025. He had been the Chief Financial Officer of Adaptimmune Therapeutics plc since March 16, 2015 until September 2019. Mr. Rawcliffe led financial strategy, management and operations functions including compliance and risk management. He has worked at Adaptimmune since 2015. He has global expertise, along with extensive business and operating experience at one of the world’s largest global healthcare companies. He served as the Chief Financial Officer of Human Genome Sciences Inc. since August 2012. He served as Senior Vice President, Finance of GSK's North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998. He was a Managing Partner and the President at SR One Ltd. from 2005 to 2006. Mr. Rawcliffe served in various roles of increasing responsibility at GlaxoSmithKline plc, including Senior Vice President Finance for North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President of Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President of Worldwide Business Development Transactions and Ventures from 2003 to 2005; Vice President of Deal Structuring from 2001 to 2003; Associate Director of Group Financial Investigations and Planning from 1999 to 2001; and Senior Analyst of Research and Genetic Projects from 1998 to 1999. Mr. Rawcliffe served as an Executive Officer PricewaterhouseCoopers LLP. began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. He has been an Independent Director of Wave Life Sciences, Inc. since February 1, 2017. He serves as a Director at Morphotek Inc. and Altiris Therapeutics, Inc. and a Board Observer at AlgoRx Pharmaceuticals, Inc. He serves as Director of Human Genome Sciences Inc. and Evergreen Fund (S.R. One Ltd.). He serves as a Director at The Pennsylvania Biotechnology Association. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW). Mr. Rawcliffe received a B.Sc. in Natural Sciences (Biochemistry) from University of Durham in England.

Positions